During the last 10 years many melanoma antigens recognized by T cells have been molecu larly characterized. This review summarizes the main features of these antigens, including both classes I and II HLA-restricted peptides, and describes their classification into diverse groups according to the tissue distribution of the antigens. The different in vitro and in vivo immunogenicity of such antigens is then discussed leading to the conclusion that Melan-A/MART-1 is the strongest among those tested being frequently recognized by patients' T cells both in vitro and in vivo. However, no correlation was found between T-cell response of melanoma patients to Melan-A/MART-1 and clinical response when it was used for vaccination. Data are also presented that suggest, through an ex vivo analysis carried out with tetramers staining of melanoma-specific T cells, that only in a limited number of advanced patients does a specific immune response develop. This response, however, appears unable to effec tively counteract metastatic melanoma growth. (Keio J Med 50 (2): 86-90, June 2001)
The molecular characterization of human tumor antigens has opened a new era in cancer immunology by allowing a more rapid translation of information gained in basic research into clinical trials of immuno therapy. t Melanoma is the tumor that was more fre quently studied thanks to several clinical reports sug gesting its antigenicity and to the availability of tumor cell lines obtainable from melanoma patients and that could be extensively used for in vitro immunological studies.' Melanoma antigens have been studied for many years at cellular level thanks to the ability to derive T cell clones from peripheral blood lympho cytes (PBL) or lymph node lymphocytes of melanoma patients. 3 Only molecular techniques, however, allowed clon ing of genes encoding such protein antigens through the screening of cDNA expression tumor libraries by cytotoxic T lymphocytes (CTL) clones." An alternative approach to the identification of tumor (melanoma) antigens was used which is also dependent on the availability of patient's T cell clones but rests on a biochemical approach. This involves extraction of antigenic peptides from major histocompatibility com plex (MHC)/peptide complexes expressed on the cell surface of tumor cells, their fractionation by re verse phase high performance liquid chromatography (HPLC), screening by anti-melanoma specific T cells and use of mass spectrometry to sequence the peptide of interest. 5 By using either of these approaches many new mela noma antigens and their epitopes recognized by T cells in the context of class I HLA have been described.1.6 More recently, techniques became available that can be used also to molecularly characterize class II HLA restricted melanoma epitopes recognized by CD4 T helper lymphocytes, a finding which paves the way to possibly more effective vaccines for the immunotherapy of melanoma patients. For a full list of these antigens see Renkvist, et al.7 
Classification of Melanoma Antigens Recognized by T Cells
According to their molecular nature and tissue dis tribution, melanoma antigens can be classified as fol lows (Table 1) This group includes antigens represented by normal proteins expressed by melanoma and other histologi cally different tumors but not by normal tissues with the exception of testis. The prototype of this group of anti gens is MAGE-1 (melanoma antigen-1), the first human tumor antigen recognized by HLA-class I-restricted T cells which has been molecularly characterized. 4 In ad dition to the well known MAGE, BAGE and GAGE families of antigens, recently a new cancer/testis antigen has been described and called NY-ESO-1 owing to the place where it was first found (New York) and the his tologically origin of the tumor (esophageous cancer) from which the antigen was isolated by using patient's serum antibodies and the Serex technique. 8 The in vitro and in vivo immunogenicity of these antigens is, in general, rather weak' and no tumor infiltrating lymphocytes (TIL) could ever be found in melanoma patients directed against these families of antigens. Generation of anti-MAGE-3 immunity both in vitro and in vivo was, however, recently obtained by using dendritic cells for its presentation to the immune system.10
Differentiation antigens recognized by class I HLA -restricted T cells
These antigens are shared between melanomas and normal melanocytes and are thus lineage-related nor mal proteins mostly involved in the biosynthesis of melanin.11 These antigens are recognized by PBL, which can be stimulated in vitro to develop antigen specific CTL.12 Moreover, TIL recognizing such anti gens in vitro in the presence of IL-2, were shown to cause clinical responses when re-infused in vivo in patients whose tumor cells express the cognate anti gen.13.14 Therefore, melanocyte differentiation anti gens appear to be immunogenic at least in a fraction of patients with a hierarchy that indicates Melan-A/ MARTI as the most immunogenic one (see below). least two members of this subgroup of tumor-specific antigens have been molecularly characterized (N acetylglucosaminyl transterase V (GnT-V) and (TRP (tyrosinase-related protein)-2-INT2)); it is of note that in both cases the immunogenic epitopes were created by the translation of retained intronic sequences. 19.20
Broadly expressed antigens

Class II HLA -restricted melanoma antigens
Immunogenicity of HLA class I-restricted melanoma antigens has been found to be weak and only occasion ally do patients develop a strong CTL reactivity after immunization with molecularly defined vaccines. Among the many possible reasons of such a phenome non, the lack of activation of T helper cells may be crucial inasmuch as CD4 T cells appear to be instru mental in eliciting a strong and sustained immune re sponse against tumor antigens.21 Therefore, it is im portant to understand whether melanoma antigens include epitopes that can activate a Th1 driven immune reaction, which may ultimately result in melanoma cell destruction. In the last few years several class II HLA restricted epitopes have been described. They fall into the group of differentiation antigens (e.g. tyrosinase, Melan-A/MART1)22.23 and cancer/testis antigens (e.g. MAGE-3, NY-ESO-1)24-26 (see Table 1 ) but, interest ing enough, several additional epitopes were found to result from point mutations or chromosomal rear rangement of a variety of normal genes (see Table  3 ).27.28 For a complete list and features of class II HLA-restricted antigens see Renkvist, et al.7 It should be pointed out that, though the molecular identification of many melanoma antigens represents a crucial progress in tumor immunology, from a practical point of view the preparation of vaccines from a single patient neoplasm (which should contain the whole spectrum of potential antigens of that particular tumor) still remains an unsolved problem. It is likely that truly Table 3 In Vitro Immunogenicity of Melanoma Antigens Immunogenicity was evaluated by induction of antigen-specific CTLs from PBL of melanoma patients after 1-5 weeks of stimulation with melanoma cells or peptide-pulsed APC. GnT-V: acetylglucosaminyl transterase V.
tumor-specific, immunogenic antigens are difficult to find and may include unique antigens that cannot be characterized in a time compatible with their use in metastatic melanoma patients in whom the tumor is progressing. However, the use of heat-shock proteins (HSP) which, at least in the mouse system, are known to bind the full repertoire of immunogenic tumor pep tides, including the unique ones, and serve as chaper ones for presentation of such peptides by dendritic cells may allow the need of antigen identification to be bypassed. 29 In fact, we have recently shown that HSP of 70Kd purified from human melanomas efficiently present known melanoma antigens to patients' T lymphocytes.30 This approach is feasible at individual patient level provided enough tumor tissue is available to purify HSP.
Recognition by T Cells in vitro and in vivo
Most of the antigens discussed above are recognized by patient's T cells in vitro after repeated stimulations and with a variable frequency in a population of mela noma patients. Results obtained by this approach, however, do not allow distinguishing between patients whose immune system was already primed in vivo against melanoma antigens owing to natural tumor growth, from patients whose T cells were primed in vitro by repeated antigenic stimulations. Nevertheless, the results of these experiments did demonstrate that patients often have T-cell precursors that can potentially recognize melanoma antigens. The question arises, however, which of the many known peptide epitopes expressed by melanoma cells were the most immunogenic ones and, therefore , the best candidates for a vaccination therapy.
Based on published data from several groups of investigators, one can establish a hierarchy in terms of in vitro immunogenicity of melanoma antigens used in the form of peptides pulsed onto antigen-presenting cells to stimulate patients' T cells (Table 3 ). From such an analysis, it appears that Melan-A/MART-1 (27 -35) is the peptide epitope more frequently recognized by patients' PBL after in vitro stimulation,3t possibly thanks to a higher frequency of T cell precursors against this antigen already present in normal donors32 as compared to other melanoma antigens. This conclu sion was corroborated by subsequent studies of ex vivo enumeration of melanoma antigen-specific T lympho cytes with tetramers,33 of immunization of HLA-A2 transgenic mice given different HLA-A2-restricted human melanoma peptides34 and, finally, of vaccination trials showing thaat melanoma patients developed anti Melan-A/MART-1 CTL responses with a frequency higher than that obtained by immunizing with gp100 or tyrosinase peptides. 35 It should be noted, however, that CTL response elicited in patients after vaccination with melanoma antigen peptides did not correlate with clin ical responses. [35] [36] [37] The availability of tetramers and the possibility to study the in vivo distribution of tetramers plus T cells and their function in vitro without the need to culture these T cells, is shedding light on the complex in teractions between melanoma growth, antigen expres sion, immune reactions and clinical outcome. In fact, Anichini and co-workers have shown that 40% of un treated metastatic melanoma patients possess Melan-A/ MART-1-specific CD45RO+ memory T cells which display tumor cytotoxicity after two weeks of culture in the presence of IL-2 while being ineffective within metastatic lesions in vivo despite the presence of the HLA-A2 restricting molecule and of the MART-1 as shown by immunohistochemistry.3S Moreover, a recent re-evaluation of melanoma patients by using MART-1 tetramers to select melanoma antigen-specific T cells has shown that the memory effector T cell phenotype (CD45RO+, CCR7-) can be found only in 25% of metastatic melanoma patients, appears late in the pro gression of the disease, and is associated with a poor prognosis.39 From these studies it can be concluded that melanoma growth in vivo may activate a specific T cell response against Melan-A/MART-1 but only after a large tumor burden has been reached, this response being then unable to efficiently control tumor growth.
This conclusion, however, is based on a few studies and on the evaluation of the T-cell response against a single melanoma antigen, namely Melan-A/MART-1, which may not necessarily reflect the general behaviour of the kinetics of the immune response to the whole, unknown spectrum of melanoma antigens.
Concluding Remarks
Many melanoma antigens recognized by T cells in the context of classes I or II MHC are now available and several of these antigens are being used as vac cines, singly or in combination (polyepitopes vaccines). However, we have still to find out how to make mela noma antigens more immunogenic to patients' immune system and to define the kinetics of the T cell response to such antigens during vaccination. The new technol ogy of tetramers now allows such an analysis to be car ried out at least for some antigens. A better knowledge of the interplay between melanoma cell antigens and the host's immune system may provide new insight to optimize future protocols of vaccination.
